European equities traded in the US as American depositary receipts were tracking higher late Wednesday morning, rising 0.63% to 1,525.33 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by consumer goods giant Unilever (UL) and petroleum refiner Equinor (EQNR), which increased 2.7% and 2.4%, respectively. They were followed by pharmaceutical company Sanofi (SNY) and brewing company Anheuser-Busch InBev (BUD), which were up 1.9% and 1.5%, respectively.
The decliners from continental Europe were led by biopharmaceutical company Cellectis (CLLS) and biotech firm Evaxion (EVAX), which lost 4.7% and 3.5%, respectively. They were followed by semiconductor company Sequans Communications (SQNS) and internet browser company Opera (OPRA), which were down 3.4% and 3.1%, respectively.
From the UK and Ireland, the gainers were led by biotech firm Trinity Biotech (TRIB) and tobacco company British American Tobacco (BTI), which advanced 25% and 2.3%, respectively. They were followed by pharmaceutical company GSK (GSK) and financial services company HSBC (HSBC), which rose 2.1% each.
The decliners from the UK and Ireland were led by biopharmaceutical companies NuCana (NCNA) and Biodexa Pharmaceuticals (BDRX), which fell 9.8% and 4.2%, respectively. They were followed by biopharmaceutical companies Adaptimmune Therapeutics (ADAP) and Mereo BioPharma Group (MREO), which dropped 2.4% each.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.